The stock price of Nektar Therapeutics (NASDAQ: NKTR) has jumped by 10.61 compared to previous close of 1.32. Despite this, the company has seen a gain of 7.35% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-03 that Nektar (NKTR) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
The 36-month beta value for NKTR is at 0.79. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NKTR is 177.94M, and currently, shorts hold a 1.75% of that float. The average trading volume for NKTR on April 30, 2024 was 2.52M shares.
NKTR’s Market Performance
NKTR stock saw an increase of 7.35% in the past week, with a monthly gain of 56.28% and a quarterly increase of 160.71%. The volatility ratio for the week is 7.54%, and the volatility levels for the last 30 days are 12.91% for Nektar Therapeutics (NKTR). The simple moving average for the past 20 days is 10.59% for NKTR’s stock, with a 112.76% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Jefferies gave a rating of “Hold” to NKTR, setting the target price at $1 in the report published on May 10th of the previous year.
NKTR Trading at 42.94% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.57% of loss for the given period.
Volatility was left at 12.91%, however, over the last 30 days, the volatility rate increased by 7.54%, as shares surge +61.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +97.30% upper at present.
During the last 5 trading sessions, NKTR rose by +7.35%, which changed the moving average for the period of 200-days by +154.53% in comparison to the 20-day moving average, which settled at $1.3480. In addition, Nektar Therapeutics saw 158.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 20,033 shares at the price of $0.68 back on Feb 20 ’24. After this action, ROBIN HOWARD W now owns 879,889 shares of Nektar Therapeutics, valued at $13,622 using the latest closing price.
Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sale 9,014 shares at $0.68 during a trade that took place back on Feb 20 ’24, which means that Zalevsky Jonathan is holding 265,025 shares at $6,130 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.81 for the present operating margin
- 0.63 for the gross margin
The net margin for Nektar Therapeutics stands at -3.06. The total capital return value is set at -0.47. Equity return is now at value -110.95, with -49.80 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -1.46. The debt to equity ratio resting at 1.01. The interest coverage ratio of the stock is -6.44.
Currently, EBITDA for the company is -129.61 million with net debt to EBITDA at -1.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.31. The receivables turnover for the company is 40.02for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.45.
Conclusion
In conclusion, Nektar Therapeutics (NKTR) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
